ClinicalTrials.gg
CompletedNCT04328077Updated Aug 9, 2022Results posted

LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of TERN-101 and Placebo in NASH - Nonalcoholic Steatohepatitis, sponsored by Terns, Inc.. Completed at 31 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-08-09.

Sponsored by Terns, Inc. (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Merck & Co., Inc.

Enrollment
6th of 10
101 · median 113
Started
2020
with 1 other
Phase 2
7 of 11
none open now
Registered
3rd of 11
by date

Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2020, is one of 7 in phase 2, and was the 3rd registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc as a file.
02

Study summary

This is a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of TERN-101 in non-cirrhotic NASH patients.

03

Conditions studied

  • NASH - Nonalcoholic Steatohepatitis

Keywords

  • Farnesoid X receptor
  • NASH
  • Nonalcoholic Steatohepatitis
  • NAFLD
  • Nonalcoholic Fatty Liver Disease
  • FXR
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 to 75 years of age
  • Overweight or obese with a (BMI) ≥ 25 kg/m2
  • Presumed NASH based on clinical characteristics or prior liver
  • ≥ 43 IU/L for men and ≥ 28 IU/L for women
  • MRI PDFF liver fat content ≥ 10 %
  • Written

Exclusion criteria

Exclusion Criteria:

  • History or clinical evidence of chronic liver diseases other than NAFLD
  • History or clinical evidence of cirrhosis, hepatic decompensation or other severe liver impairment
  • History of liver transplant, or current placement on a liver transplant list
  • Total > 1.2 mg/dL
  • Albumin \< 3.5 g/dL
  • > 1.1
  • or ALT > 5 x
  • ALP > 156 IU/L
  • count \< 150,000 /mm3
  • \< 60 mL/min/1.73m2
  • Weight loss > 5% within past 3 months prior to Screening
  • Uncontrolled diabetes
  • Uncontrolled hyperlipidemia
  • Active COVID-19 infection
  • Other protocol-defined inclusion/exclusion criteria could apply
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    TERN-101 dose level 1

    Orally administered.

    Drug: TERN-101

  • Experimental
    TERN-101 dose level 2

    Orally administered.

    Drug: TERN-101

  • Experimental
    TERN-101 dose level 3

    Orally administered.

    Drug: TERN-101

  • Placebo comparator
    Placebo

    Orally administered.

    Other: Placebo

Interventions

  • DrugTERN-101

    Investigational drug

  • OtherPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events for TERN-101 Versus Placebo

    Time frame: 16 weeks

Secondary outcomes

  1. Percent Change From Baseline in ALT Outcome Measure

    Time frame: 12 weeks

  2. Plasma Concentration of TERN-101 - AUC 0-24

    Area under the curve

    Time frame: 12 weeks (0-24 hours post dose)

  3. Plasma Concentration of TERN-101 - Cmax

    Maximum observed concentration

    Time frame: 12 Weeks (0-72 hours post dose)

  4. Plasma Concentration of TERN-101 - Tmax

    Time to reach maximum measured plasma concentration

    Time frame: 12 Weeks (0-72 hours post dose)

  5. Plasma Concentration of TERN-101 - t1/2

    Determination of half-life

    Time frame: 12 Weeks (0-72 hours post dose)

07

Results

Posted Jun 14, 2022

Participant flow

Participant flow — Overall Study
MilestonePlaceboTERN-101 5mgTERN-101 10mgTERN-101 15mg
Started26252624
Completed26232521
Not completed0213
Withdrew: Lost to follow-up0100
Withdrew: Withdrawal by subject0113

Outcome measures

PrimaryNumber of Participants With Adverse Events for TERN-101 Versus Placebo
Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events for TERN-101 Versus Placebo
ParticipantsPlaceboTERN-101 5 mgTERN-101 10 mgTERN-101 15 mg
Number of Participants With Adverse Events for TERN-101 Versus Placebo10131415
SecondaryPercent Change From Baseline in ALT Outcome Measure
Time frame:
12 weeks
Reported as:
Least squares mean · percentage of change from baseline
Percent Change From Baseline in ALT Outcome Measure
percentage of change from baselinePlaceboTERN-101 5 mgTERN-101 10 mgTERN-101 15 mg
Percent Change From Baseline in ALT Outcome Measure-5.33 ± 6.606-2.63 ± 6.743-17.99 ± 6.646-13.22 ± 7.246
Statistical analysis
  • Placebo vs TERN-101 5 mg · ANCOVA · p = 0.7755 · Mean difference (final values): 2.70 · 95% CI -16.1 to 21.5
  • Placebo vs TERN-101 10 mg · ANCOVA · p = 0.1798 · Mean difference (final values): -12.66 · 95% CI -31.3 to 5.9
  • Placebo vs TERN-101 15 mg · ANCOVA · p = 0.4229 · Mean difference (final values): -7.90 · 95% CI -27.4 to 11.6
SecondaryPlasma Concentration of TERN-101 - AUC 0-24

Area under the curve

Time frame:
12 weeks (0-24 hours post dose)
Reported as:
Geometric mean · h*ng/mL
Plasma Concentration of TERN-101 - AUC 0-24
h*ng/mLTERN-101 5mgTERN-101 10mgTERN-101 15mg
Plasma Concentration of TERN-101 - AUC 0-241380 ± 96.71470 ± 29.72510 ± 13.3
SecondaryPlasma Concentration of TERN-101 - Cmax

Maximum observed concentration

Time frame:
12 Weeks (0-72 hours post dose)
Reported as:
Geometric mean · ng/mL
Plasma Concentration of TERN-101 - Cmax
ng/mLTERN-101 5 mgTERN-101 10 mgTERN-101 15 mg
Plasma Concentration of TERN-101 - Cmax116 ± 45.0155 ± 158.8389 ± 19.0
SecondaryPlasma Concentration of TERN-101 - Tmax

Time to reach maximum measured plasma concentration

Time frame:
12 Weeks (0-72 hours post dose)
Reported as:
Median · hour
Plasma Concentration of TERN-101 - Tmax
hourTERN-101 5 mgTERN-101 10 mgTERN-101 15 mg
Plasma Concentration of TERN-101 - Tmax1 (0 to 6)1 (0 to 3)0.5 (0.5 to 1)
SecondaryPlasma Concentration of TERN-101 - t1/2

Determination of half-life

Time frame:
12 Weeks (0-72 hours post dose)
Reported as:
Median · hour
Plasma Concentration of TERN-101 - t1/2
hourTERN-101 5 mgTERN-101 10 mgTERN-101 15 mg
Plasma Concentration of TERN-101 - t1/214.6 (8.7 to 67.8)6.75 (4 to 7.9)6 (5.8 to 11.3)

Adverse events

Collected over 16 Weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/26 (0%)1/26 (3.8%)10/26 (38.5%)
TERN-101 5mg0/25 (0%)0/25 (0%)13/25 (52%)
TERN-101 10mg0/26 (0%)0/26 (0%)14/26 (53.8%)
TERN-101 15mg0/23 (0%)1/23 (4.3%)15/23 (65.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboTERN-101 5mgTERN-101 10mgTERN-101 15mg
Urinary tract infectionInfections and infestations0/260/250/261/23
COVID-19 pneumoniaInfections and infestations1/260/250/260/23
Most frequent other events
Showing 10 of 59
Most frequent other events
EventPlaceboTERN-101 5mgTERN-101 10mgTERN-101 15mg
PruritusSkin and subcutaneous tissue disorders0/263/253/264/23
HeadacheNervous system disorders2/261/253/262/23
DiarrhoeaGastrointestinal disorders2/260/250/262/23
ConstipationGastrointestinal disorders2/261/251/261/23
Decreased appetiteMetabolism and nutrition disorders1/260/252/261/23
DizzinessNervous system disorders1/261/252/260/23
COVID-19Infections and infestations0/261/251/261/23
AnxietyPsychiatric disorders1/260/250/261/23
Asymptomatic COVID-19Infections and infestations0/261/250/261/23
FatigueGeneral disorders0/260/251/261/23

Baseline characteristics

Safety Population: All patients who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)PlaceboTERN-101 5mgTERN-101 10mgTERN-101 15mgTotal
<=18 years00000
Between 18 and 65 years2624232194
>=65 years01326
Age, Continuous
Age, Continuous(years)PlaceboTERN-101 5mgTERN-101 10mgTERN-101 15mgTotal
Mean50.4 ± 11.0048.0 ± 12.3252.5 ± 13.6451.6 ± 9.4950.6 ± 11.71
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTERN-101 5mgTERN-101 10mgTERN-101 15mgTotal
Female1615171765
Male10109635
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboTERN-101 5mgTERN-101 10mgTERN-101 15mgTotal
White2123212186
Black or African American21205
Asian11103
American Indian or Alaskan Native00000
Native Hawaiian or Other Pacific Islander00000
Other20226
Unknown00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboTERN-101 5mgTERN-101 10mgTERN-101 15mgTotal
Hispanic or Latino2017161770
Not Hispanic or Latino689427
Not Reported00011
Unknown00112
Region of Enrollment
Region of Enrollment(Participants)PlaceboTERN-101 5mgTERN-101 10mgTERN-101 15mgTotal
United States26252623100
ALT
ALT(U/L)PlaceboTERN-101 5mgTERN-101 10mgTERN-101 15mgTotal
Mean55.51 ± 23.63956.25 ± 16.26660.84 ± 29.07555.79 ± 26.44757.15 ± 24.064
Diabetes Mellitus Status
Diabetes Mellitus Status(Participants)PlaceboTERN-101 5mgTERN-101 10mgTERN-101 15mgTotal
Absent1514101554
Present111116846
08

Study locations

31 sites
  • Terns Clinical Study Site 1017
    Chandler, Arizona 85224, United States
  • Terns Clinical Study Site 1018
    Tucson, Arizona 85712, United States
  • Terns Clinical Study Site 1024
    Tucson, Arizona 85712, United States
  • Terns Clinical Study Site 1004
    Coronado, California 92117, United States
  • Terns Clinical Study Site 1035
    Fresno, California 93720, United States
  • Terns Clinical Study Site 1013
    La Jolla, California 92037, United States
  • Terns Clinical Study Site 1016
    Los Angeles, California 90036, United States
  • Terns Clinical Study Site 1008
    Montclair, California 91763, United States
  • Terns Clinical Study Site 1001
    Panorama City, California 91402, United States
  • Terns Clinical Study Site 1012
    Gainesville, Florida 32610, United States
  • Terns Clinical Study Site 1007
    Hialeah, Florida 33013, United States
  • Terns Clinical Study Site 1028
    Hialeah, Florida 33014, United States
  • Terns Clinical Study Site 1009
    Miami, Florida 33166, United States
  • Terns Clinical Study Site 1033
    Orlando, Florida 32806, United States
  • Terns Clinical Study Site 1032
    Indianapolis, Indiana 46202, United States
  • Terns Clinical Study Site 1010
    Bastrop, Louisiana 71220, United States
  • Terns Clinical Study Site 1037
    New Orleans, Louisiana 70121, United States
  • Terns Clinical Study Site 1023
    Shreveport, Louisiana 71105, United States
  • Terns Clinical Study Site 1002
    Baltimore, Maryland 21202, United States
  • Terns Clinical Study Site 1011
    Boston, Massachusetts 02118, United States
  • Terns Clinical Study Site 1038
    Florham Park, New Jersey 07932, United States
  • Terns Clinical Study Site 1027
    Durham, North Carolina 27710, United States
  • Terns Clinical Study Site 1014
    Hermitage, Tennessee 37076, United States
  • Terns Clinical Study Site 1005
    Arlington, Texas 76012, United States
  • Terns Clinical Study Site 1025
    Georgetown, Texas 78628, United States
  • Terns Clinical Study Site 1021
    Houston, Texas 77030, United States
  • Terns Clinical Study Site 1029
    Houston, Texas 77030, United States
  • Terns Clinical Study Site 1006
    San Antonio, Texas 78215, United States
  • Terns Clinical Study Site 1003
    San Antonio, Texas 78229, United States
  • Terns Clinical Study Site 1019
    San Antonio, Texas 78229, United States
  • Terns Clinical Study Site 1022
    Seattle, Washington 98105, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in May 2021, 11 months.

Results were first posted in Jun 2022, 1 year after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 11 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2020
First posted
Mar 31, 2020
StartActual
Jun 18, 2020
Primary completionActual
May 19, 2021
CompletionActual
May 19, 2021
Results first posted
Jun 14, 2022
Last update
Aug 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04328077
Lead sponsor
Terns, Inc.
Responsible party
Sponsor
First posted
Mar 31, 2020
Start date
Jun 18, 2020
Primary completion
May 19, 2021
Completion
May 19, 2021
Results posted
Jun 14, 2022
Last update
Aug 9, 2022

Study contacts

clinicaltrials@ternspharma.com
study director · Terns, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion